Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations

NCT06969963 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Bioequivalence Study in Healthy Subjects

Interventions

DRUG: Lepsiramp, 0.5 Mg/mL Oral Suspension
DRUG: Fycompa, 0.5 Mg/mL Oral Suspension

Sponsor

Aya Mohammed Abdel Magid Abdel Hamid

Collaborators

[object Object]
[object Object]